UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 2, 2020

Precision BioSciences, Inc.

(Exact name of registrant as specified in its charter)

001-38841

20-4206017 (IRS Employer Identification No.)

Delaware (State or other jurisdiction of incorporation)

(Commission File Number)

302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701 (Address of principal executive offices) (Zip Code)

(919) 314-5512

(Registrant's telephone number, including area code)

 $$\mathbf{N}/\!A$$ (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.000005 per share	DTIL	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

As previously announced, Precision BioSciences, Inc. (the "Company") will be presenting at the Jefferies Virtual Healthcare Conference on June 3, 2020. A copy of the accompanying presentation materials that the Company will discussing in meetings with investors and analysts is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. These presentation materials are also available on the Investor Relations page of the Company's website at https://investor.precisionbiosciences.com.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

Description

(d) Exhibits

Exhibit No

99.1 <u>Precision Biosciences, Inc. Presentation as of June 2, 2020</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRECISION BIOSCIENCES, INC.

By: /s/ Dario Scimeca Dario Scimeca General Counsel

Date: June 2, 2020

DTIL



Dedicated to Improving Life.

June 2020

Overcome cancer. Cure genetic disease. Feed the planet.

Forward Looking Statements



This presentation (together with any other statements or information that we may make in connection herewith) may contain forward-looking statements. All statements other than statements of present and historical facts contained in this prospectus, including without limitation, statements regarding our future results of operations and financial position, business strategy and approach, including related results, prospectus, planned preclinical or greenhouse studies and clinical or field trials, including expected products, planned preclinical or greenhouse studies and clinical or field trials, including expected production levels and manufacturing timeframes, of our manufacturing facility, management's expectations regarding pipelines and milestones for product candidates and our food editing platform, and timing and likelihood of success, as well as plans and objectives of management for future operations, may be forward-looking statements. Without limiting the foregoing, the words "aim", "anticipate," "believe," "could," "expect," "should," "plan," "intend," "estimate," "target," "may," "will," "would," "potential," the negative thereof and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements, or achievements, and one should avoid placing undue reliance on such statements.

Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to: our ability to become profitable; our ability to procure sufficient funding and requirements under our current debt instruments; our limited operating history; the success of our programs and product candidates in which we expend our resources; our dependence on our ARCUS technology; the initiation, cost, timing, progress and results of research and development activities, preclinical or greenhouse studies and clinical or field trials; our or our collaborators' ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the laws and regulatory landscape applicable to our and our collaborators' development of product candidates; our ability to achieve our anticipated operating efficiencies at our manufacturing facility; delays or difficulties in enrolling patients in clinical trials; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriate of intellectual property ingulationary associated with applicable healthcare, data privacy and security regulations and our compliance therewith; the rate and degree of market acceptance of any of our product candidates; risks associated with applicable healthcare, data privacy and security regulations and our compliance therewith; the rate and degree of market acceptance of any of our product candidates; risks associated with applicable healthcare, data privacy and security regulations and our compliance therewith; the rate and degree of market acc

All forward-looking statements speak only as of the date of this presentation, and except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

This presentation may also contain estimates, projections, and/or other information regarding our industry, our business and the markets for certain of our product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, clinical trials, studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.

Delivering on the Promise of Genome Editing





ARCUS genome editing platform built for translation with full freedom to operate

Clinical stage allogeneic CAR T platform with validating initial safety and response data

Scaled in-house *cGMP* manufacturing

pioneers in

World class team


Strong balance sheet: \$154.2m cash^{*} funds into 2H 2021 *In vivo* gene correction platform seeking to cure genetic and infectious diseases

Wholly integrated food editing platform focused on human wellness and food security

000

* As of March 31, 2020







Ability to produce **ARCUS-based CAR T** and *in vivo* therapies

MCAT: Manufacturing Center for Advanced Therapeutics




Advanced Therapeutics
17,300 sq. ft. facility in Durham, NC
Fully cGMP compliant
Operational July 2019

Currently producing clinical trial material for **BCMA CAR T program**




The Allogeneic CAR T Opportunity




Four Key Requirements for Allogeneic CAR T Success






Key Features of Precision's Allogeneic CAR T Platform



Ka

Platform Is Delivering Against All Four Key Requirements




*Clinical data from PBCAR0191 DL1 & DL2 interim update presented in December 2019; n=6 NHL patients and n=3 ALL patients

Precision's Off-the-Shelf CAR T Immunotherapy Pipeline

Product Candidates	Program Area	Discovery	Pre-clinical	Clinical	Rights
PBCAR0191 (CD19)	NHL and ALL – Phase	1 Data Expected 20)20		
PBCAR20A (CD20)	NHL, CLL, SLL – First P	atient Dosed April	2020	\rightarrow /	1
PBCAR269A (BCMA)	MM – IND cleared – P	hase 1 Dosing Expe	ected 2020	У	

Three allogeneic CAR T programs expected to be in clinical trials in 2020

Allogeneic CAR T Study Designs



*FDA approved study to skip DL1 (3.0 x 10⁵ cells/kg) and begin dosing at DL2 based on PBCAR0191 safety profile.




1	ン
	8


System Organ Class Preferred Term, n(%)	NHL (n=6)	B-ALL (n=3)
CRS (Cytokine Release Syndrome) – Grade 1 or Grade 2	2 (33%)	1 (33%)
ICANS (Immune Effector Cell Neurotoxicity) – Grade 1 or Grade 2	0 (0%)	1 (33%)
CRS Grade 3 or higher	0 (0%)	0 (0%)
ICANS Grade 3 or higher	0 (0%)	0 (0%)
GvHD (Graft versus Host Disease)	0 (0%)	0 (0%)
Infection	0 (0%)	0 (0%)

*Clinical data from PBCAR0191 D1 & DL2 interim update presented in December 2019; DL1 = 3.0 x 10⁵ cells/kg; DL2 = 1.0 x 10⁵ cells/kg.















Curing Genetic Disease

In Vivo Gene Correction










ARCUS Platform Delivers Against All Four Key Requirements



1



* as assessed by oligo capture technique PCSK9 data reported in part in Wang et al, Nature Biotechnology, 2018

In Vivo Gene Correction Pipeline




Product Candidate	Program Area	Discovery	Pre-clinical	Clinical	Rights
HBV	Chronic Hepatitis B –	IND 2021			GILEAD
HAO1	Primary hyperoxalur	atype 1 (PH1)			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Fransthyretin	Familial amyloid poly	vneuropathy			~ 🗞
АроСЗ	Lipoprotein lipase de	ficiency			<
PCSK9	Familial hypercholes	terolemia			K

PH1 selected as lead wholly-owned *in vivo* program

Overview of Primary Hyperoxaluria Type 1 (PH1)









2

ARCUS <u>efficiently knocked-out the *HAO1* gene</u> in non-human primates following AAV8 delivery

ARCUS treatment resulted in <u>~70% reduction</u> in urine oxalate in a PH1 mouse model









Elo is Focused on Delivering Healthy and Sustainable Food Sources












Key Takeaways









Dedicated To Improving Life